Chaudhary joins imre with more than two decades of experience leading top holding company agencies and practices and advising global clients across all industries with deep expertise for clients invested in healthcare across pharmaceutical, biotech, medical device, health tech, consumer health, payor and health systems.
If you are not happy with the results below please do another search
50 search results for:
TauRx announced preliminary results Thursday from the Phase III LUCIDITY study, showing hydromethylthionine mesylate (HMTM), an inhibitor of tau aggregates, could slow Alzheimer’s disease progression or cognitive decline.
Provention Bio entered a co-promotion agreement with Sanofi Thursday ahead of the possible November approval of Type 1 diabetes drug teplizumab.
Eli Lilly and Co. said on Thursday the U.S. Food and Drug Administration (FDA) had agreed to a quick review of its diabetes drug Mounjaro to treat obesity, months after a study showed it helped people lose more than 20% of their weight.
Nested Therapeutics, a precision oncology company targeting previously undruggable cancer targets, closed on a $90 million Series A financing, bringing total financing to $125 million since its inception in 2021.
India is testing samples of cough syrups produced by Maiden Pharmaceuticals after the World Health Organization said its products were linked to the deaths of dozens of children in Gambia, a government official said on Thursday.
More than 60 abortion clinics across 15 states have stopped providing abortions since the U.S. Supreme Court overturned Roe v. Wade in June, according to a study by the Guttmacher Institute, a reproductive rights advocacy research group.
GSK reported Wednesday its checkpoint inhibitor Jemperli yielded positive data in non-small cell lung cancer, moving the monoclonal antibody potentially closer to the market in this indication.
A U.S. bankruptcy judge has blocked New Mexico and Mississippi from pursuing lawsuits accusing Johnson & Johnson of misleading consumers about the safety of its talc products, such as its baby powder, for now.
Amylyx is dipping back into the well to raise funds to launch its recently approved ALS drug Relyvrio. The company plans to offer 6 million shares in a public offering to bring in between $167 to $192.2 million.